O	0	1	A
O	2	12	randomized
O	13	18	phase
O	19	21	II
O	22	27	trial
O	28	30	of
B-intervention	31	39	platinum
I-intervention	40	45	salts
O	46	48	in
O	49	54	basal
O	54	55	-
O	55	59	like
O	60	66	breast
O	67	73	cancer
O	74	82	patients
O	83	85	in
O	86	89	the
O	90	101	neoadjuvant
O	102	109	setting
O	109	110	.

O	111	118	Results
O	119	123	from
O	124	127	the
O	128	134	GEICAM
O	134	135	/
O	135	139	2006
O	139	140	-
O	140	142	03
O	142	143	,
O	144	155	multicenter
O	156	161	study
O	161	162	.

O	163	175	Chemotherapy
O	176	183	remains
O	184	186	as
O	187	190	the
O	191	195	only
O	196	204	systemic
O	205	214	treatment
O	215	221	option
O	222	231	available
O	232	235	for
O	236	241	basal
O	241	242	-
O	242	246	like
O	247	253	breast
O	254	260	cancer
O	261	262	(
O	262	264	BC
O	264	265	)
O	266	274	patients
O	274	275	.

O	276	287	Preclinical
O	288	294	models
O	295	298	and
O	299	306	several
O	307	312	phase
O	313	315	II
O	316	323	studies
O	324	333	suggested
O	334	338	that
O	339	347	platinum
O	348	353	salts
O	354	357	are
O	358	364	active
O	365	370	drugs
O	371	373	in
O	374	378	this
O	379	381	BC
O	382	389	subtype
O	390	396	though
O	397	402	there
O	403	405	is
O	406	408	no
O	409	419	randomized
O	420	425	study
O	426	436	supporting
O	437	441	this
O	442	452	hypothesis
O	452	453	.

O	454	458	This
O	459	464	study
O	465	477	investigates
O	478	480	if
O	481	484	the
O	485	493	addition
O	494	496	of
O	497	508	carboplatin
O	509	511	to
O	512	513	a
O	514	525	combination
O	526	528	of
O	529	531	an
O	532	542	alkylating
O	543	548	agent
O	549	557	together
O	558	562	with
O	563	577	anthracyclines
O	578	581	and
O	582	589	taxanes
O	590	592	is
O	593	597	able
O	598	600	to
O	601	609	increase
O	610	613	the
O	614	622	efficacy
O	623	625	in
O	626	629	the
O	630	641	neoadjuvant
O	642	651	treatment
O	652	659	context
O	659	660	.

B-eligibility	661	669	Patients
I-eligibility	670	674	with
I-eligibility	675	683	operable
I-eligibility	684	690	breast
I-eligibility	691	697	cancer
I-eligibility	698	701	and
I-eligibility	702	722	immunophenotypically
I-eligibility	723	730	defined
I-eligibility	731	736	basal
I-eligibility	736	737	-
I-eligibility	737	741	like
I-eligibility	742	749	disease
I-eligibility	750	751	(
I-eligibility	751	753	ER
I-eligibility	753	754	-
I-eligibility	754	755	/
I-eligibility	755	757	PR
I-eligibility	757	758	-
I-eligibility	758	759	/
I-eligibility	759	763	HER2
I-eligibility	763	764	-
I-eligibility	765	768	and
I-eligibility	769	780	cytokeratin
I-eligibility	781	782	5
I-eligibility	782	783	/
I-eligibility	783	784	6
I-eligibility	784	785	+
I-eligibility	786	788	or
I-eligibility	789	793	EGFR
I-eligibility	793	794	+
I-eligibility	794	795	)
O	796	800	were
O	801	810	recruited
O	810	811	.

O	812	820	Patients
O	821	825	were
O	826	836	randomized
O	837	839	to
O	840	847	receive
O	848	850	EC
O	851	852	(
O	852	862	epirubicin
O	863	865	90
O	866	868	mg
O	868	869	/
O	869	870	m
O	870	871	(
O	871	872	2
O	872	873	)
O	874	878	plus
O	879	895	cyclophosphamide
O	896	899	600
O	900	902	mg
O	902	903	/
O	903	904	m
O	904	905	(
O	905	906	2
O	906	907	)
O	908	911	for
O	912	913	4
O	914	920	cycles
O	920	921	)
O	922	930	followed
O	931	937	either
O	938	940	by
B-intervention	941	942	D
I-intervention	943	944	(
I-intervention	944	953	docetaxel
O	954	957	100
O	958	960	mg
O	960	961	/
O	961	962	m
O	962	963	(
O	963	964	2
O	964	965	)
O	966	967	×
O	968	969	4
O	970	976	cycles
O	976	977	;
B-intervention	978	980	EC
I-intervention	980	981	-
I-intervention	981	982	D
O	982	983	)
O	984	986	or
O	987	990	DCb
O	991	992	(
O	992	1001	docetaxel
O	1002	1004	75
O	1005	1007	mg
O	1007	1008	/
O	1008	1009	m
O	1009	1010	(
O	1010	1011	2
O	1011	1012	)
O	1013	1017	plus
O	1018	1029	carboplatin
O	1030	1033	AUC
O	1034	1035	6
O	1036	1037	×
O	1038	1039	4
O	1040	1046	cycles
O	1046	1047	;
B-control	1048	1050	EC
I-control	1050	1051	-
I-control	1051	1054	DCb
O	1054	1055	)
O	1055	1056	.

O	1057	1060	The
O	1061	1068	primary
O	1069	1072	end
O	1073	1078	point
O	1079	1082	was
B-outcome-Measure	1083	1095	pathological
I-outcome-Measure	1096	1104	complete
I-outcome-Measure	1105	1113	response
I-outcome-Measure	1114	1115	(
I-outcome-Measure	1115	1118	pCR
I-outcome-Measure	1118	1119	)
O	1120	1122	in
O	1123	1126	the
O	1127	1133	breast
O	1134	1143	following
O	1144	1147	the
O	1148	1154	Miller
O	1155	1158	and
O	1159	1164	Payne
O	1165	1173	criteria
O	1173	1174	.

B-total-participants	1175	1181	Ninety
I-total-participants	1181	1182	-
I-total-participants	1182	1186	four
O	1187	1195	patients
O	1196	1200	were
O	1201	1211	randomized
O	1212	1213	(
O	1213	1215	46
O	1216	1218	EC
O	1218	1219	-
O	1219	1220	D
O	1220	1221	,
O	1222	1224	48
O	1225	1227	EC
O	1227	1228	-
O	1228	1231	DCb
O	1231	1232	)
O	1232	1233	.

B-outcome	1234	1237	pCR
I-outcome	1238	1242	rate
I-outcome	1243	1245	in
I-outcome	1246	1249	the
I-outcome	1250	1256	breast
O	1257	1260	was
O	1261	1265	seen
O	1266	1268	in
B-iv-bin-abs	1269	1271	16
O	1272	1280	patients
O	1281	1282	(
B-iv-bin-percent	1282	1284	35
I-iv-bin-percent	1285	1286	%
O	1286	1287	)
O	1288	1292	with
O	1293	1295	EC
O	1295	1296	-
O	1296	1297	D
O	1298	1301	and
B-cv-bin-abs	1302	1304	14
O	1305	1313	patients
O	1314	1315	(
B-cv-bin-percent	1315	1317	30
I-cv-bin-percent	1318	1319	%
O	1319	1320	)
O	1321	1325	with
O	1326	1328	EC
O	1328	1329	-
O	1329	1332	DCb
O	1333	1334	(
O	1334	1335	P
O	1336	1341	value
O	1342	1343	=
O	1344	1345	0
O	1345	1346	.
O	1346	1348	61
O	1348	1349	)
O	1349	1350	.

B-outcome	1351	1354	pCR
I-outcome	1355	1357	in
I-outcome	1358	1361	the
I-outcome	1362	1368	breast
I-outcome	1369	1372	and
I-outcome	1373	1379	axilla
O	1380	1383	was
O	1384	1388	seen
O	1389	1391	in
B-iv-bin-percent	1392	1394	30
I-iv-bin-percent	1395	1396	%
O	1397	1399	of
O	1400	1408	patients
O	1409	1411	in
O	1412	1416	both
O	1417	1421	arms
O	1421	1422	.

O	1423	1426	The
B-outcome	1427	1434	overall
I-outcome	1435	1443	clinical
I-outcome	1444	1452	response
I-outcome	1453	1457	rate
O	1458	1461	was
B-iv-bin-percent	1462	1464	70
I-iv-bin-percent	1465	1466	%
O	1467	1468	(
O	1468	1470	95
O	1471	1472	%
O	1473	1475	CI
O	1476	1478	56
O	1478	1479	-
O	1479	1481	83
O	1481	1482	)
O	1483	1485	in
O	1486	1489	the
O	1490	1492	EC
O	1492	1493	-
O	1493	1494	D
O	1495	1498	arm
O	1499	1502	and
B-cv-bin-percent	1503	1505	77
I-cv-bin-percent	1506	1507	%
O	1508	1509	(
O	1509	1511	95
O	1512	1513	%
O	1514	1516	CI
O	1517	1519	65
O	1519	1520	-
O	1520	1522	87
O	1522	1523	)
O	1524	1526	in
O	1527	1530	the
O	1531	1533	EC
O	1533	1534	-
O	1534	1537	DCb
O	1538	1541	arm
O	1541	1542	.

B-outcome	1543	1548	Grade
I-outcome	1549	1550	3
I-outcome	1550	1551	/
I-outcome	1551	1552	4
I-outcome	1553	1561	toxicity
O	1562	1565	was
O	1566	1573	similar
O	1574	1576	in
O	1577	1581	both
O	1582	1586	arms
O	1586	1587	.

O	1588	1591	The
O	1592	1600	addition
O	1601	1603	of
O	1604	1615	carboplatin
O	1616	1618	to
O	1619	1631	conventional
O	1632	1644	chemotherapy
O	1645	1649	with
O	1650	1652	EC
O	1652	1653	-
O	1653	1654	D
O	1655	1657	in
O	1658	1663	basal
O	1663	1664	-
O	1664	1668	like
O	1669	1675	breast
O	1676	1682	cancer
O	1683	1691	patients
O	1692	1695	did
O	1696	1699	not
O	1700	1707	improve
O	1708	1711	the
O	1712	1720	efficacy
O	1721	1729	probably
O	1730	1737	because
O	1738	1742	they
O	1743	1746	had
O	1747	1754	already
O	1755	1763	received
O	1764	1766	an
O	1767	1777	alkylating
O	1778	1783	agent
O	1783	1784	.

O	1785	1790	These
O	1791	1799	findings
O	1800	1806	should
O	1807	1809	be
O	1810	1815	taken
O	1816	1820	into
O	1821	1834	consideration
O	1835	1839	when
O	1840	1850	developing
O	1851	1854	new
O	1855	1861	agents
O	1862	1865	for
O	1866	1870	this
O	1871	1878	disease
O	1878	1879	.
